CleveMed is pleased to share important news from our parent company, Beacon Biosignals, which has announced the successful completion of an $86 million funding round. This investment will accelerate the advancement of Beacon’s cutting-edge artificial intelligence technologies aimed at understanding and improving brain health, with the goal of transforming the diagnosis, monitoring, and treatment of neurological, sleep, and psychiatric conditions.
As a member of the Beacon Biosignals family, CleveMed continues to play a vital role in advancing sleep and neurodiagnostic care. CleveMed’s home sleep testing technologies and services are utilized in more than 10,000 sleep studies each month by health systems across the United States. The new investment will further strengthen CleveMed’s ability to expand its reach, enhance operational capabilities, and integrate next-generation technologies into its diagnostic offerings.
At this pivotal moment in the adoption of artificial intelligence within healthcare, Beacon Biosignals and CleveMed remain steadfast in their commitment to the rigorous and responsible application of machine learning to advance the quality, precision, and accessibility of neurodiagnostic and sleep care worldwide.
Read the full press release from Beacon Biosignals HERE.
